Third Rock Ventures Ii, L.p. - Net Worth and Insider Trading
Third Rock Ventures Ii, L.p. Net Worth
The estimated net worth of Third Rock Ventures Ii, L.p. is at least $395 Million dollars as of 2024-11-13. Third Rock Ventures Ii, L.p. is the 10% Owner of Revolution Medicines Inc and owns about 5,666,214 shares of Revolution Medicines Inc (RVMD) stock worth over $336 Million. Third Rock Ventures Ii, L.p. is the 10% Owner of Jounce Therapeutics Inc and owns about 9,387,176 shares of Jounce Therapeutics Inc (JNCE) stock worth over $18 Million. Third Rock Ventures Ii, L.p. is also the 10% Owner of MyoKardia Inc and owns about 77,652 shares of MyoKardia Inc (MYOK) stock worth over $17 Million. Besides these, Third Rock Ventures Ii, L.p. also holds Global Blood Therapeutics Inc (GBT) , Blueprint Medicines Corp (BPMC) , Sage Therapeutics Inc (SAGE) , Allena Pharmaceuticals Inc (ALNAQ) . Details can be seen in Third Rock Ventures Ii, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Third Rock Ventures Ii, L.p. has not made any transactions after 2021-06-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Third Rock Ventures Ii, L.p.
Third Rock Ventures Ii, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Third Rock Ventures Ii, L.p. owns 7 companies in total, including Revolution Medicines Inc (RVMD) , MyoKardia Inc (MYOK) , and Allena Pharmaceuticals Inc (ALNAQ) among others .
Click here to see the complete history of Third Rock Ventures Ii, L.p.’s form 4 insider trades.
Insider Ownership Summary of Third Rock Ventures Ii, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RVMD | Revolution Medicines Inc | 2021-06-04 | 10 percent owner |
| MYOK | MyoKardia Inc | 2018-03-07 | 10 percent owner |
| ALNAQ | Allena Pharmaceuticals Inc | 2017-11-06 | 10 percent owner |
 | | 2017-03-02 | 10 percent owner |
| | 2017-02-07 | 10 percent owner |
| | 2021-05-25 | 10 percent owner |
| | 2016-05-16 | 10 percent owner |
Third Rock Ventures Ii, L.p. Latest Holdings Summary
Third Rock Ventures Ii, L.p. currently owns a total of 7 stocks. Among these stocks, Third Rock Ventures Ii, L.p. owns 5,666,214 shares of Revolution Medicines Inc (RVMD) as of June 4, 2021, with a value of $336 Million and a weighting of 85.1%. Third Rock Ventures Ii, L.p. owns 9,387,176 shares of Jounce Therapeutics Inc (JNCE) as of May 25, 2021, with a value of $18 Million and a weighting of 4.47%. Third Rock Ventures Ii, L.p. also owns 77,652 shares of MyoKardia Inc (MYOK) as of September 26, 2017, with a value of $17 Million and a weighting of 4.42%. The other 4 stocks Global Blood Therapeutics Inc (GBT) , Blueprint Medicines Corp (BPMC) , Sage Therapeutics Inc (SAGE) , Allena Pharmaceuticals Inc (ALNAQ) have a combined weighting of 6.02% among all his current holdings.
Latest Holdings of Third Rock Ventures Ii, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RVMD | Revolution Medicines Inc | 2021-06-04 | 5,666,214 | 59.36 | 336,346,463 |
| JNCE | Jounce Therapeutics Inc | 2021-05-25 | 9,387,176 | 1.88 | 17,647,891 |
| MYOK | MyoKardia Inc | 2017-09-26 | 77,652 | 224.91 | 17,464,711 |
| GBT | Global Blood Therapeutics Inc | 2017-03-02 | 191,501 | 68.49 | 13,115,903 |
| BPMC | Blueprint Medicines Corp | 2017-02-07 | 106,493 | 96.63 | 10,290,419 |
| SAGE | Sage Therapeutics Inc | 2016-05-16 | 65,226 | 5.73 | 373,745 |
| ALNAQ | Allena Pharmaceuticals Inc | 2017-11-06 | 2,790,964 | 0.00 | 0 |
Holding Weightings of Third Rock Ventures Ii, L.p.
Third Rock Ventures Ii, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Third Rock Ventures Ii, L.p. has made a total of 2 transactions in Revolution Medicines Inc (RVMD) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Revolution Medicines Inc is the sale of 543,113 shares on June 4, 2021, which brought Third Rock Ventures Ii, L.p. around $16 Million.
According to the SEC Form 4 filings, Third Rock Ventures Ii, L.p. has made a total of 4 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Jounce Therapeutics Inc is the sale of 552,520 shares on May 25, 2021, which brought Third Rock Ventures Ii, L.p. around $4 Million.
According to the SEC Form 4 filings, Third Rock Ventures Ii, L.p. has made a total of 0 transactions in MyoKardia Inc (MYOK) over the past 5 years. The most-recent trade in MyoKardia Inc is the sale of 601,400 shares on September 26, 2017, which brought Third Rock Ventures Ii, L.p. around $26 Million.
More details on Third Rock Ventures Ii, L.p.'s insider transactions can be found in the Insider Trading History of Third Rock Ventures Ii, L.p. table.Insider Trading History of Third Rock Ventures Ii, L.p.
- 1
Third Rock Ventures Ii, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Third Rock Ventures Ii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Third Rock Ventures Ii, L.p. is -24.24%. GuruFocus also compares Third Rock Ventures Ii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Third Rock Ventures Ii, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Third Rock Ventures Ii, L.p.'s insider trading performs compared to the benchmark.
Performance of Third Rock Ventures Ii, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 39.5 | | | | | |
| Relative Return to S&P 500(%) | 38.03 | | | | | |
Third Rock Ventures Ii, L.p. Ownership Network
Ownership Network List of Third Rock Ventures Ii, L.p.
Ownership Network Relation of Third Rock Ventures Ii, L.p.
Third Rock Ventures Ii, L.p. Owned Company Details
What does Revolution Medicines Inc do?
Who are the key executives at Revolution Medicines Inc?
Third Rock Ventures Ii, L.p. is the 10 percent owner of Revolution Medicines Inc. Other key executives at Revolution Medicines Inc include General Counsel Jeff Cislini , director & See Remarks Mark A Goldsmith , and See Remarks Stephen Michael Kelsey .
Revolution Medicines Inc (RVMD) Insider Trades Summary
Over the past 18 months, Third Rock Ventures Ii, L.p. made no insider transaction in Revolution Medicines Inc (RVMD). Other recent insider transactions involving Revolution Medicines Inc (RVMD) include a net sale of 34,044 shares made by Jeff Cislini , a net sale of 186,391 shares made by Stephen Michael Kelsey , and a net sale of 265,672 shares made by Mark A Goldsmith .
In summary, during the past 3 months, insiders sold 249,942 shares of Revolution Medicines Inc (RVMD) in total and bought 0 shares, with a net sale of 249,942 shares. During the past 18 months, 718,995 shares of Revolution Medicines Inc (RVMD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 718,995 shares.
Revolution Medicines Inc (RVMD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Revolution Medicines Inc Insider Transactions
Third Rock Ventures Ii, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Third Rock Ventures Ii, L.p.. You might contact Third Rock Ventures Ii, L.p. via mailing address: 29 Newbury Street, 3rd Floor, Boston Ma 02116.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
